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Zaprinast accelerates recovery from established acute renal
failure in the rat
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Zaprinast accelerates recovery from established acute renal failure in
the rat. Atrial natriuretic factor (ANF) has been demonstrated to be
effective in the treatment of acute renal failure (ARF) in both rat and
humans. The biological effects of ANF are presumed to be mediated by
the generation of intracellular 3',5'-cyclic guanosine monophosphate
(cGMP). Therefore, the current investigation examined whether zaprinast
(M&B 22948), a guanosine 3',5'-cyclic monophosphate (cGMP)-specific
phosphodiesterase inhibitor, would be effective in the treatment of
established acute renal failure in the rat. Acute renal failure was induced
by 60 minutes of bilateral renal artery clamping. Twenty-four hours after
the ischemic insult, rats received either vehicle (5% Dextrose), zaprinast
(0.03 or 0.3 mg/kg/mm) or ANF24 (0.2 jsg/kg/min) intravenously for four
hours. Renal function, as measured by daily serum creatinine (days 1 to 7)
and day 2 inulin clearances, was dramatically improved by zaprinast but
not ANF treatment. Forty-eight hours post-renal ischemia, glomerular
filtration rate (GFR) was 0.14 0.04 (ml!min/100 g body wt) in the vehicle
and 0.94 0.29 in the zaprinast treated animals. To evaluate the
mechanism by which zaprinast accelerated renal recovery, we measured
regional blood flow in the postischemic rat kidneys during drug treatment
with a laser doppler flowmeter. Both high and low dose zaprinast
significantly increased cortical (17%) and outer medullary blood flow
(40% and 60%), an effect not seen with ANF. In summary, zaprinast is
effective in the treatment of established ischemic ARF. The mechanism by
which zaprinast accelerates renal recovery is due to its unique ability to
stimulate regional renal blood flow and increase intracellular cGMP in the
setting of tissue ischemia.
Acute renal failure is a major problem in contemporary medi-
cine. Five percent of all hospitalized patients are affected by some
degree of acute renal dysfunction [11. Fifty percent of all patients
diagnosed with ARF will die, thus demonstrating the morbidity
and mortality associated with this disease [21. In various clinical
situations, such as intensive care medicine, following cardiovascu-
lar surgery and after cadaveric renal transpiantion, the incidence
of acute renal failure has been reported to be between 50% and
75% [1, 3]. Under most conditions, it is not possible to predict
who will develop ARF. Thus, identification of a pharmacologic
intervention that would be effective in the treatment of estab-
lished renal failure would be a significant therapeutic break-
through.
Proposed pathophysiologic mechanisms for ARF include tubu-
lar obstruction and/or vasoconstruction [4]. ANF increases GFR
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and stimulates tubular fluid and sodium flow [5—8]; therefore, it
should be ideal in the treatment of ischemic ARF. Recent
experimental studies have shown that both ischemic and nephro-
toxic ARF may be effectively attenuated by ANF or ANF syn-
thetic analogues administered before or after the onset of renal
injury [9—18].
ANF, as well as its synthetic analogues, stimulates the activation
of the particulate guanylate cyclase, thus increasing intracellular
cGMP production. Intracellular cyclic GMP appears to mediate
many of the biological functions of ANF [19—21]. Interestingly,
inhibition of nitric oxide (NO), an activator of the soluble
guanylate cyclase, by LNGnitroarginine worsens ischemic renal
dysfunction [22, 231. These results indicate that cGMP may be the
common denominator responsible for the improvement seen in
ARF in response to ANF or NO. Another strategy to increase the
intracellular level of cGMP is by inhibiting its degradation to the
corresponding nucleoside 5'-monophosphate. This hydrolysis is
catalyzed by cyclic nucleotide phosphodiesterases (PDEs) which
exist in multiple distinct forms in many tissues [24—27]. These
PDE isozymes represent the sole mechanism for degrading cGMP
and cyclic adenosine monophosphate (cAMP), and therefore play
an important role in determining their intracellular concentration.
Previous studies have demonstrated that zaprinast (M&B 22948;
2-o-propoxyphenyl-8-azapurin-6-one), is a selective inhibitor of
the cGMP-specific-PDE (PDE-V) [28], and therefore should
mimic the biologic properties of natriuretic peptides as well as
NO. In this regard, zaprinast elevates intracellular cGMP, pro-
duces a dose-dependent decrease in arterial pressure, and also
elicits a significant natriuresis [29, 30]. Therefore, the current
study was designed to evaluate whether zaprinast would be an
effective therapy in the treatment of established acute renal
failure in the rat.
Methods
Renal injury and treatment
Male Sprague-Dawley rats (weight 320—400 g) were fed stan-
dard rat chow (Purina) and allowed free access to tap water. On
the day of surgery, rats were anesthetized with sodium pentobar-
bital given intraperitoneally (50 mg/kg). The kidneys were ac-
cessed through an abdominal midline incision and both the right
and left renal arteries were occluded with smooth vascular clamps
for 60 minutes. Twenty-four hours after the ischemic insult,
conscious restrained animals received a four hour infusion, via the
femoral vein, of either a 5% dextrose solution (D5W), high dose
zaprinast (0.30 mg/kg/mm), low dose zaprinast (0.03 mg/kg/mm),
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or ANF24 (0.2 g/kgImin). All drugs were dissolved in D5W and
infused at a rate of 0,03 mI/mm.
Physiological parameters
The rat's femoral artery was catheterized with PE-50 tubing for
blood pressure measurements. Mean arterial pressure (MAP) was
measured every 30 minutes during the four hour drug infusion
with a Harvard blood pressure monitor (model VT-15C). Urine
was collected one hour prior to drug infusion and each hour
during drug infusion for volume, sodium, cAMP and cGMP
quantitation. At the end of the four hour drug infusion, rats were
put into individual metabolic cages for three days, with free access
to food and water, in order to quantitate daily urinary cGMP
excretion. Urinary cGMP and cAMP were measured using a
commercial enzyme immunometric assay (ETA) (Caymen Chem-
icals, Ann Arbor, MI, USA). Urine volume was measured gravi-
metrically, urine sodium was determined by flame photometry
(Instrumentation Laboratory, model 943). Tail vein blood was
collected daily for determination of serum creatinine. Two sepa-
rate groups of rats underwent inulin clearance determinations 24
hours after the infusion of zaprinast (0.03 mg/kg/mm) or vehicle.
Inulin clearances were performed as before [31].
Regional blood flow measurements
Renal ischemia was produced as described above. Twenty four
hours after renal ischemia, rats were anesthetized with intraperi-
toneal sodium pentobarbital (50 mg/kg). Catheters were placed in
the trachea (PE-lO, Clay Adams), left femoral vein and artery
(PE-50, Clay Adams). The left kidney was exposed through a
midline incision, decapsulated, and immobilized. The exposed
kidney was maintained at 37°C by bathing it in mineral oil warmed
by a heating lamp. Regional blood flow was measured by a laser
doppler flowmeter (model ALF21D; Transonic Systems Inc.,
Ithaca, NY, USA). Flow probes were mounted on micromanipu-
lators. Cortical flow was measured by resting the probe on the
kidney surface, and medullary flow was measured by inserting the
probe 3.0 to 4.5 mm into the renal parenchyma. At the end of the
experiment, probe placement was verified by visual inspection of
the probe tract. After one hour equilibration, animals were
infused with D5W, zaprinast (0.03 or 0.30 mg/kg/mm), or ANF24
(200 ng/kg/min) as described above. Blood flow was measured
every 30 minutes during four hours of drug infusion.
Reagents
ANF24 and zaprinast were provided by the Monsanto Corpo-
ration (St. Louis, MO, USA). Inulin was purchased from Sigma
Chemical Co. (St. Louis, MO, USA).
Statistics
Statistics were performed using the statistical analysis software
package (Instat; GraphPad, San Diego, CA, USA). All data were
expressed as mean standard error of the mean (sEM). Statistical
analysis was performed by two way analysis of variance and
Student's t-test was used to evaluate the significance of difference.
A probability of less than 0.05 was considered statistically signif-
icant.
Results
Sixty minutes of bilateral renal artery clamping resulted in a
significant decrease in renal function as measured by serum
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Fig. 1. Effect of zaprinast and ANF on established ischemic ARE. Serum
creatinine was determined daily after 60 minutes of bilateral renal arterial
clamping. Drugs were infused for four hours only on day 1. Symbols are:
(•) zaprinast 0.3 mg/kg/mm, N = 4; (El) zaprinast 0.03 mg/kg/mm, N = 6;
(open circle) ANF 200 ng/kg/min, N 8; (closed circle) D5W, N = 6.
Values are the mean SEM of at least four determinations. < 0.01,
*P < 0.05 versus D5W group.
creatinine (Fig. 1). In order to ensure similar degrees of ischemia
induced ARF, only animals with 24-hour post-ischemic serum
creatinine of 3.0 to 4.5 mg/dl were included for further study. Two
days after renal ischemia, rats infused with D5W experienced a
further decline in renal function as evidenced by a serum creati-
nine peak of 5.3 0.6 mg/dl. In contrast, animals receiving
zaprinast experienced a significant increase in their renal function
24 hours following drug infusion. Serum creatinine decreased to
2.9 0.3 mg/dl and 3.0 0.4 mg/dl after treatment with low dose
and high dose zaprinast, respectively. Furthermore, serum creat-
mine levels remained significantly lower in the zaprinast treated
animals for six days post-ischemia when compared to the vehicle
treated control group. Both low and high dose zaprinast proved to
be equally efficacious. Since ANF has been demonstrated to
ameliorate established ischemic ARF [9, 10, 15, 16], we elected to
compare the relative potency of ANF24 (0.2 rg/kg/min) versus
zaprinast in our animals. This dose of ANF was chosen because it
proved to be pharmacologically similar to low dose zaprinast in its
ability to decrease mean arterial pressure (MAP) (Fig. 2). We
noted a trend for ANF to decrease serum creatinine as compared
to vehicle infusion; however, this did not reach statistical signifi-
cance. Therefore, at the doses which produced the similar effects
on arterial blood pressure, zaprinast is significantly more potent in
alleviating established ischemic ARF when compared to ANF.
To ensure that serum creatinine measurements were a true
reflection of renal function, we determined GFR by measuring
inulin clearance. In two separate groups of animals, we measured
GFR 24 hours after treatment with either D5W or zaprinast (0.03
mg/kg/mm). As seen in Table 1, GFR was significantly greater in
the zaprinast treated rats (0.94 0.29 ml/min/100 g body wt) as
compared to the vehicle treated animals (0.14 0.04 ml/min/100
g body wt). These data confirm that in these animals, serum
creatinine is an accurate representation of renal function, and
indeed zaprinast increases GFR in established ARF.
The beneficial effects of zaprinast on ARF demonstrated no
dose-dependence. However, a clear dose-dependent relationship
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Fig. 2. Effect of zaprinast and ANF on mean arterial pressure (M4P) in
established ischemic ARF. MAP was measured in awake rats every 30
minutes during drug infusion. The data are expressed as an absolute
change in mm Hg from MAP measured prior to drug infusion. Symbols
are: (U) zaprinast 0.3 mg/kg/mm, ([II) zaprinast 0.03 mg/kg/mm, (open
circle) ANF 0.2 ng/kg/min; (closed circle) D5W. Values are expressed as
the mean SEM of at least four determinations. **p < *p < 0.05
versus D5W.
Table 1. Effect of zaprinast on glomerular filtration rate in established
acute renal failure
1
0 0.5 1.0 1.5 2.0 2.5 3.0 3.5 4.0
0
D5W zap 0.03 zap 0.3 ANF
Group
Serum creatinine
mgldl
Inulin clearance
ml/min/100 g body wt
D5W 4.35 0.79 0.14 0.04
Zap 0.03 1.85 0.20a 0.94 0.29k'
Fig. 3. Effect of zaprinast and ANF on urinary sodium excretion in estab-
lished ARE. Rat urine was collected hourly during four hours of drug
infusion. Symbols are: (LI) before drug infusion, (U) during the fourth
hour of drug infusion. Abbreviations are: zap 0.3, zaprinast 0.3 mg/kg/mm;
zap 0.03, zaprinast 0.03 mg/kg/mm; ANF, 200 ng/kg/min. Values are
expressed as the mean SEM of at least four determinations. p < 0.05
versus pre UNaV.
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Fig. 4. Effect of zaprinast and ANF on urinary cGMP excretion in estab-
lished ARF. Urine was collected hourly prior to and during drug infusion.
Symbols are: (LI) zero hour; (U) 4 hours; (diagonal stripe box) 1 day;
(vertical stripe box) 2 days; (grey screen box) 3 days. After the drug
infusions, animals were placed in individual metabolic cages and urine was
collected for 24 hours. Urinary cGMP values were normalized for urinary
creatinine levels in order to normalize for the degree of renal dysfunction
in the various animal groups. Abbreviations are: zap 0.3, zaprinast 0.3
mg/kg/mm; zap 0.03, zaprinast 0.03 mg/kg/mm; ANF, 200 ng/kg/min.
Values are expressed as the mean SEM of at least four determinations.
< 0.01, 'P < 0.05 versus predrug infusion levels.
evaluate their effect on regional renal blood flow in order to
explain the greater potency of zaprinast on renal recovery. One
day after an ischemic insult, cortical blood flow in the rat kidney
was higher than pre-ischemic levels (39.0 vs. 35.4 ml/min/100 g
tissue). However, medullary blood flow was only about 50% (5.6
vs. 11.8 ml/min/100 g tissue) of pre-ischemic levels (Fig. 5). Both
high dose and low dose zaprinast increased cortical blood flow in
the postischemic kidney by approximately 17%. At four hours of
drug infusion, low dose and high dose zaprinast increased med-
ullary blood flow by 60% and 40%, respectively. These values
were not statistically different from each other. These data are
ap < 0.05
was established for blood pressure, urinary sodium excretion
(UNaV), and urinary cGMP excretion. High dose zaprinast max-
imally lowered MAP 34 mm Hg, while MAP decreased only 20
mm Hg in response to low dose zaprinast (Fig. 2). Sodium
excretion (Fig. 3) was not altered by low dose zaprinast, while high
dose zaprinast significantly increase UNaV, twofold, during the
fourth hour of drug infusion. ANF increased urinary sodium
excretion comparable to that of high dose zaprinast (Fig. 3).
Lastly, urinary cGMP excretion (pmol/mg creatinine) increased
from basal levels of 210 29 to 519 103 in response to low dose
zaprinast and 2570 486 after four hours of high dose zaprinast
infusion. ANF increased urinary cGMP excretion to a similar
degree as high dose zaprinast (Fig. 4).
To test the specificity of zaprinast for cGMP versus cAMP
metablolism, we measured the urinary excretion of cAMP in
response to drug infusion. Urinary cAMP excretion was not
significantly affected by zaprinast infusion. Urinary cAMP excre-
tion (pmol/mg creatinine) in response to low dose zaprinast was
1155 519 versus 1849 492 in pre-drug versus the fourth hour
of drug infusion, respectively. In response to high dose zaprinast,
urinary cAMP excretion was 1354 287 versus 1618 379 in
pre-drug versus the fourth hour of drug infusion, respectively.
These data indicate the specificity of zaprinast as an inhibitor of
cGMP metabolism in the rat kidney.
Since high dose zaprinast and ANF demonstrated similar
effects on renal electrolyte and cGMP excretion, we sought to
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consistent with both high and low dose zaprinast demonstrating
equal efficacy on the functional recovery of the kidney after an
ischemic insult. ANF had no stimulatory effect on regional renal
blood flow. On the contrary, ANF decreased cortical blood flow
by 24% and medullary blood flow by 42% in the postischemic
kidney (Fig. 6).
ANF has been demonstrated to have a short circulating half-life
even in nephrectomized animals [321; therefore, renal cGMP
synthesis should return to basal levels soon after the end of the
ANF infusion. Because the metabolism and clearance of zaprinast
is currently unknown, we evaluated the synthesis of cGMP in the
kidney for three days following the end of the zaprinast infusion.
As seen in Figure 4, urinary cGMP excretion remained elevated
for 24 hours after the end of low dose zaprinast and 72 hours after
the end of high dose zaprinast infusion. In contrast, urinary cOMP
excretion returned to basal levels 24 hours after the end of the
ANF infusion.
Discussion
The kidney is a remarkably regenerative organ. A significant
decrease in renal artery blood flow will result in tubular epithelial
cell destruction, vascular congestion, and a decrease in GFR. The
decrease in GFR is most likely a result of both tubular obstruction
and afferent arteriolar vasoconstriction [4]. In most circumstances,
the kidney will recover from such an insult; however, in many
cases this will not be prior to the need for temporary dialysis or
the onset of other complications associated with ARF. Numerous
nonpharmacologic and pharmacologic strategies have been at-
tempted to enhance recovery from an acute ischemic injury. These
include inducing an osmotic diuresis with mannitol, the use of
loop diuretics to maintain high tubular urine flow rates, and the
low dose infusion of dopamine to increase GFR [1, 33, 34]. More
recently, exogenous administration of peptides such as ANF [9,
10, 15, 16] and insulin-like growth factor I [23, 31] have been
infused in pharmacologic doses and have accelerated renal recov-
ery and regeneration.
At least two receptors for ANF exist in the mammalian kidney.
The guanylate cyclase coupled receptor mediates the synthesis of
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cUMP, and the non-guanylate cyclase receptor whose function
appears to be involved in the clearance of the peptide [35—38].
The physiological effects of ANF on the kidney, such as natriure-
sis, vasodilation and stimulation of GFR, are thought to be
mediated by intracellular cGMP. This is substantiated by the fact
that zaprinast, a selective inhibitor of the cGMP specific phos-
phodiesterase (PDE-V), is both hypotensive and natriuretic in
vivo [291. We elected to evaluate whether zaprinast would be
effective in the amelioration of established ischemic ARF for two
reasons: first, to determine whether the effect of ANF on ischemia
induced ARF is mediated by cGMP, and second, whether zapri-
nast will also inhibit the degradation of cGMP originating from
the soluble guanylate cyclase. Since NO may be involved in the
pathophysiology of ischemic ARF [22, 23], we might expect
zaprinast to be more efficacious in the treatment of ARF than
either ANF or NO alone.
In humans, ischemic ARF is mostly diagnosed only after
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A Cortex
Fig. 5. Regional renal blood flow in the normal and postischemic kidney.
Both cortical and medullary blood flow were measured in normal and
postischemic kidneys. Symbols are: (LII) normal kidney, N = 10; (•)
postischemic kidney, N = 18. Values are expressed as the mean SEM.
**p < P < 0.05 versus normal kidney.
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Fig. 6. Effect of zaprinast and ANF on the regional renal blood flow in the
postischemic rat kidney. Regional renal blood flow was measured in
postischemic kidneys every 30 minutes following drug infusion. Data are
expressed as the percentage changes from pre-drug treatment. A, cortex.
B, medulla. Symbols are: (•) zaprinast 0.3 mg/kg/mm; (LI) zaprinast 0.03
mg/kg/mm; (C)) ANF 200 ng/kg/min; (S) vehicle infusion. Values are
expressed as the mean SEM of at least four determinations. **p < 0.01,
*p < 0.05 versus D5W group.
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significant renal dysfunction has already been established. There-
fore, identification of a drug which would effectively stimulate
renal recovery of established injury would have the greatest
clinical utility. For this reason, we elected to study the effect of
zaprinast in a rat model of established ischemic ARF. Our
experimental protocol consisted of infusing zaprinast, ANF, or
vehicle 24 hours after the acute ischemic insult for a period of only
four hours. Two doses of zaprinast were tested in this model: low
dose zaprinast, which has been demonstrated to be natriuretic in
a rat model of heart failure [39], and ten times this dose (high
dose). Zaprinast significantly improved renal function, as mea-
sured by serum creatinine, but also caused a significant hypoten-
sion. MAP decreased approximately 34 mm Hg in the high dose
group of animals. Interestingly, low dose zaprinast, which lowered
MAP only 20 mm Hg, was equally as efficacious as the high dose
drug. The reason for the absence of a dose-response relationship
was hypothesized to be either: (1) high dose zaprinast was
significantly hypotensive such that the kidney incurred a second
ischemic insult, (2) low dose zaprinast is a maximally saturating
concentration of drug in regards to PDE-V inhibition, or (3) the
rate of renal recovery and regeneration was already maximized at
low dose zaprinast. In regards to the first hypothesis, it is possible
that inhibition of the hypotensive response to high dose zaprinast
by co-adminstration of dopamine may have proven to be a more
effective therapy, especially since dopamine has been used to
maintain arterial pressure during the infusion of hypotensive
doses of ANF [11, 15]. Further studies will need to be performed
to evaluate this possibility. We proved the second hypothesis to be
incorrect because high dose zaprinast was more potent as an
arterial vasodilator, natriuretic agent, and stimulator of urinary
cGMP excretion than low dose zaprinast. Finally, our study was
not designed to evaluate whether the rate of renal recovery was
maximized with low dose zaprinast. Future studies will have to be
designed to evaluate the efficacy of lower doses of zaprinast on
ARF.
ANF has a short circulating half-life (T112) even in bilateral
nephrectomized animals [32]. The majority of ANF is cleared
from the blood by the cellular internalization of its clearance
receptor [37, 38], and what ANF is filtered by the kidney is
metabolized by a neutral endopeptidase in the proximal tubule
brush border [40, 41]. The metabolism of zaprinast and its serum
or renal T112 is currently unknown. Therefore, we hypothesized
that the increased potency of zaprinast was a result of an
increased serum or renal T112 for this drug as compared to ANF.
An alternative hypothesis would be that zaprinast, unlike ANF,
would potentiate both the renal natriuretic peptide and NO
systems. To evaluate the first hypothesis, we measured the urinary
excretion of cGMP for three days after the end of the intravenous
infusions of both zaprinast and ANF. As expected, ANF induced
renal cGMP synthesis returned quickly to basal levels within 24
hours after the end of drug administration. However, the effects of
zaprinast were significantly prolonged. Urinary cGMP excretion
remained significantly elevated 24 hours after low dose and 72
hours after high dose zaprinast infusion. These data suggest that
the greater potency of zaprinast than ANF may be due to its
prolonged effects on the postischemic kidney. The molecular
weight of zaprinast is 271 g/mol and would be expected to be
freely filtered by the glomerulus. However, whether the prolonged
effects of zaprinast can be attributed to its concentration in the
kidney or because of elevated blood levels remains to be deter-
mined.
It is also possible that zaprinast is more potent than ANF
because the effects of this drug on the kidney are mediated by
both ANF and C-type natriuretic peptide (CNP). Similar to ANF,
CNP lowers blood pressure and stimulates sodium excretion in
the rat [421. ANF and CNP are both synthesized in the rat kidney
[43—46]. ANF in the distal nephron and CNP in both the proximal
and distal nephron. Furthermore, like the ANF receptor, the CNP
receptor contains a guanylate cyclase domain that upon CNP
binding generates cGMP. Therefore, the beneficial effects of
zaprinast may be a result of its effects on both the proximal and
distal nephron.
The beneficial effects of ANF on the postischemic kidney are
thought to be due to its ability to increase GFR and stimulate
sodium and urine flow. The cellular mechanism of zaprinast's
effect on renal recovery was not directly addressed by the exper-
iments in this study; however, we can infer some mechanisms from
our data. Low dose zaprinast did not significantly increase UNaV
as compared to vehicle treated animals during the four hour
infusion of the drug, while ANF significantly increased UNaV.
Therefore, we can dissociate the natriuresis induced by zaprinast
as an important mechanism in recovery from ischemic ARF.
Furthermore, acute elevations of renal cGMP will also not
significantly contribute to the recovery of renal function, as
evidenced by the much greater increase in urinary cGMP excre-
tion in response to ANF versus low dose zaprinast. However, we
cannot rule out that a continuous three day infusion of ANF (0.2
gfkgImin) would be more efficacious than the four-hour low dose
zaprinast infusions.
Since low dose zaprinast had negligible effects on tubular fluid
flow, we sought to evaluate the effect of this drug on regional renal
blood flow. Ischemia results in a significant decrease in medullary
blood flow, a region which has poor oxygenation even in the
normal kidney. This decrease in blood flow is thought to be caused
by vascular obstruction secondary to erythrocyte aggregation, an
effect mainly confined to the medulla [47]. In our rats, medullary
blood flow in the postischemic kidney was severely depressed as
compared to cortical blood flow. Although a depressed medullary
blood flow cannot directly decrease GFR and tubular filtration, it
might influence these parameters indirectly by inhibiting tubular
solute absorption in the thick ascending limb and thus activate the
tubuloglomerular feedback mechanism. Zaprinast, both low and
high doses, similarly increased blood flow in the postischemic
kidney. Interestingly, both doses had a greater effect on medullary
as compared to cortical blood flow. Therefore, we hypothesize
that zaprinast increases GFR and tubular function in the post-
ischemic kidney by selectively stimulating the medullary circula-
tion. This would explain why both high and low doses of zaprinast
were equally as efficacious on the functional recovery of the
kidney after an ischemic insult. Previous studies have demon-
strated that ANF acutely increases GFR by dilating the afferent
while constricting the efferent glomerular arteriole [7, 48]. There-
fore, one would not expect ANF to increase blood flow in the
renal microvasculature. Indeed, renal blood flow is unchanged or
even decreased in normal kidney following ANF treatment [49—
511, and our studies also indicate that the doses of ANF used
depressed both cortical and medullary blood flow while markedly
stimulating renal solute and cGMP excretion. These data further
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demonstrate the importance of the renal microcirculation in the
functional recovery of the kidney from postischemic ARF.
Finally, we also confirmed that zaprinast is a highly specific
inhibitor of cGMP metabolism. Low dose and high dose zaprinast
increased the urinary excretion of cGMP by approximately three-
fold and twelvefold, respectively. Neither dose of zaprinast stim-
ulated the urinary excretion of cAMP. These results indicate that
if the pharmacologic effects of zaprinast on the recovery of
established ARF are mediated by a cyclic nucleotide, then its
effects must be attributed to cGMP, not cAMP.
Interestingly, the localization of the inducible NO synthase in
the rat kidney is highest in concentration in the outer medulla,
specifically the thick ascending limbs, collecting duct and vasa
recta [52]. This is the location in the kidney where zaprinast has its
greatest effect on blood flow. Our studies clearly demonstrate that
ANF decreases medullary blood flow while zaprinast increases
medullary blood flow. Studies by Brezis et al have also indicated
that NO may regulate medullaty blood flow in the kidney, and
nitrovasodilatation may play an important role in the prevention
of medullary hypoxic injury [53]. Therefore, it is possible that
zaprinast stimulates renal recovery from an acute ischemic insult
by potentiating the medullary NO system.
In summary, inhibition of renal cGMP metabolism appears to
be a reasonable therapeutic strategy for the treatment of estab-
lished ischemic ARF. This is accomplished with a drug, zaprinast,
that is a selective inhibitor of the Type-V phosphodiesterase
isozyme. The potential benefit of this drug as compared to ANF is
its greater potency to stimulate recovery from established isch-
emic ARF at doses that are less hypotensive. A full dose response
curve was not generated for zaprinast, and it is possible that
smaller, non-hypotensive doses would also be equally efficacious.
Therefore, we suggest that monotherapy with zaprinast may be a
better therapeutic modality in the treatment of ischemic ARF
than multidrug therapy with ANF plus a peripheral vasoconstric-
tor. Second, zaprinast was efficacious at doses that had no effect
on UNaV, suggesting one need not be as concerned with intravas-
cular volume and electrolyte shifts that may result from ANF
therapy. Finally, these data suggest that the increase in the
medullary circulation may significantly contribute to renal synthe-
sis of cGMP and may be an important mechanism contributing to
the regenerative capacity of this organ.
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